Disease Landscape and Forecast Insights

With a drug-treated population of about 2.5 million in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of…

Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of SCCHN for each country, as…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key squamous cell carcinoma of the head and neck patient populations,…

Clarivate Epidemiology’s coverage of squamous cell carcinoma of the head and neck comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the…

Since the approval of immune checkpoint inhibitors, the treatment of bladder cancer has been transformed. Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now options in earlier…

Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market,…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

Epilepsy is a heterogeneous condition requiring individualized treatment, and a substantial number of patients are treatment-refractory. Neurologists consider many factors when selecting an…

Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic…

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals…

Epilepsy is a heterogeneous condition requiring individualized treatment, especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…

MARKET OUTLOOK The severe to very severe chronic obstructive pulmonary disease (COPD) drug market is becoming increasingly crowded as several LAMAs, LABA/ICSs, LABA/LAMAs, and, most recently,…